Why Did Plus Therapeutics Stock Soar 12.78%? Insider Buying Sparks Bullish Sentiment

On August 26, 2025, Plus Therapeutics' stock surged by 12.78% in pre-market trading, reflecting a significant bullish sentiment among investors.

One of the key drivers behind this surge was the recent insider buying activity. Robert P. Lenk, a director at Plus Therapeutics, acquired 110,000 shares of the company's common stock on August 22, 2025, at a price of $0.4889 per share. This purchase increased his direct ownership to 139,327 shares, as disclosed in a Form 4 filing. Insider buying often signals confidence in the company's future prospects, which can attract other investors and drive up the stock price.

This insider activity comes at a time when Plus Therapeutics is likely focusing on strategic initiatives and potential growth opportunities. The market's positive response to Lenk's purchase suggests that investors are optimistic about the company's direction and potential for future success.